Search
Paliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. … It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnZomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. … The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalThe use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigationalTamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalCipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types ...
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigational- a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. … [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood
Mineral oil
go.drugbank.com/drugs/DB11057ApprovedInvestigationalVet approvedIt is also used as a mild laxative for human or veterinary uses. … Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnThis drug presented different dosages and it was administered as a capsule or suspension. … It was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawn[A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA. … In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive.